Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Colchicine and Atrial Fibrillation Trial
2022-500850-40-01Phase 3Authorised
- Sponsor
- Gentofte Hospital
- Start
- Sep 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Colchicine with Placebo (2 arms). Primary endpoint: Time to first AF admission from start of medication. Planned start Sep 2022; status: authorised.
02
Drugs
colchicine
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on 2022-500850-40-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500850-40-01.